|

Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.

RECRUITINGSponsored by Salome Kristensen
Actively Recruiting
SponsorSalome Kristensen
Started2023-08-01
Est. completion2026-06-01
Eligibility
Age50 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06011512

Summary

The goal of this observational study is to expand the knowledge about development and aggreviation of diabetes mellitus in patients with giant cell arthritis and polymyalgia rheumatica. The main questions it aims to answer are: * To identify the risk of comorbidities, especially diabetes, in patients with giant cell arthritis and polymyalgia rheumatica, treated with glucocorticoids in combination with or without interleukin-6 inhibitor. * To identify clinical outcomes and biomarkers as potential predictors for development or aggregation of already existing diabetes mellitus in patients with giant cell arthritis or polymyalgia rheumatica using machine learning prediction. Participants will be followed at their respective rheumatology clinic, and will be asked to deliver blood samples at predefined visits.

Eligibility

Age: 50 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Men or women aged 50 to 85 years
* Are diagnosed with GCA or PMR
* Diagnosis is established by or confirmed by a rheumatologist (clinical expert opinion)
* Speak and understand Danish
* Are able to give signed and dated informed consent

Exclusion Criteria:

* None

Conditions5

ArthritisDiabetesGiant Cell ArteritisLarge Vessel VasculitisPolymyalgia Rheumatica

Browse More Trials

Diabetes trialsArthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.